EGFR and hepatocellular carcinoma: In summary, we proposed that dihydrotanshinone I targets EGFR with good antitumor activity, compared to counterpart studies on dihydrotanshinone I. Our findings identified EGFR as a valuable therapeutic target and reveal that dihydrotanshinone I may serve as a potential and promising oncotherapeutic agent for HCC treatment.